Dezhan Healthcare Co Ltd. Stock Analysis 000813.SZ

Dezhan Healthcare Co., Ltd. is engaged the research, development, production and sales of chemical drugs, preparations and biological peptides. The company is headquartered in Beijing, Beijing and currently employs 1,067 full-time employees. The firm mainly engages in pharmaceutical business. The Company’s products include cardiovascular drugs such as Atorvastatin Calcium Tablets, Amlodipine Atorvastatin Calcium Tablets, Warfarin Sodium Tablets, Trimetazidine Hydrochloride Capsules/Tablets, Amiodarone Hydrochloride Tablets, as well as other drugs including Famciclovir Tablets, Azathioprine Tablets, Hydroxyurea Tablets, and Colchicine Tablets. The firm is involved in biopharmaceuticals, peptide raw materials, and industrial hemp-related products, and is expanding into healthcare services such as medical rehabilitation and elderly care. The firm's products and solutions are mainly applied in cardiovascular disease treatment, chronic disease management, and healthcare services. The firm mainly operates in the domestic market.